Nasopharyngeal Carcinoma (NPC)
Conditions
Keywords
nasopharyngeal carcinoma, nab-paclitaxel, concurrent chemotherapy
Brief summary
The goal of this clinical trial is to determine the maximum tolerated dose and the recommended phase II dose for nab-paclitaxel when administered concurrently with radiotherapy in nasopharyngeal carcinoma. Researchers will observe the toxicity response of patients receiving nab-paclitaxel at 180 mg/m², 200 mg/m², 230 mg/m², and 260 mg/m².
Interventions
DRUGNab-paclitaxel
All participants enrolled in the study will be treated with nab-paclitaxel during radical radiotherapy following induction chemotherapy. The doses are increased progressively (180 mg/m², 200 mg/m², 230 mg/m², and 260 mg/m²).
Sponsors
Sun Yat-sen University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Pathologically confirmed nasopharyngeal carcinoma * III-IVa (AJCC8th) * age 18-70 * PS score 0-1 * normal functions to tolerate chemotherapy and radiotherapy
Exclusion criteria
* The presence of other malignant neoplasms within the preceding five years, with the exception of carcinoma in situ, adequately treated non-melanoma skin cancer and papillary thyroid cancer, is permitted. * Symptomatic heart failure, unstable angina, myocardial infarction, active infections requiring systemic therapy, psychiatric disorders, or family and social factors
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The maximum tolerated dose and the recommended phase II dose | From start of radiotherapy to 2 weeks after completion of radiotherapy | The maximum tolerated dose and the recommended phase II dose for nab-paclitaxel when administered concurrently with radiotherapy. |
Countries
China
Contacts
Primary ContactFang-Yun Xie
Backup ContactPu-Yun OuYang
Outcome results
None listed